Gene modifications in the PmrAB and PhoPQ two-component regulatory systems, as well as inactivation of the mgrB gene, are known to be causes of colistin resistance in Klebsiella pneumoniae. The objective of this study was to characterise the mechanism involved in colistin resistance in a Klebsiella oxytoca isolate. A K. oxytoca clinical isolate showing resistance to colistin was recovered in Cali, Colombia. The pmrA, pmrB, phoP, phoQ and mgrB genes were amplified and sequenced. Wild-type mgrB genes from K. pneumoniae and K. oxytoca were cloned, and corresponding recombinant plasmids were used for complementation assays. By analysing the mgrB gene of the K. oxytoca isolate and its flanking sequences, an insertion sequence (IS) of 1196 bp was identified in its promoter region. The insertion was located between nucleotides −39 and −38 when referring to the start codon of the mgrB gene, thus negatively interfering with expression of the mgrB gene by modifying its promoter structure. This IS was very similar to ISKpn26 (99% nucleotide identity) belonging to the IS5 family. Complementation assays with mgrB genes from wild-type K. pneumoniae or K. oxytoca restored full susceptibility to colistin. In conclusion, here we identified the mechanism involved in colistin resistance in a K. oxytoca isolate. Modulation of mgrB gene expression was the key factor for this acquired resistance to colistin.
Introduction
Klebsiella oxytoca and Klebsiella pneumoniae are frequent sources of nosocomial infections and the sources of nosocomial outbreaks [1, 2] . The occurrence of multidrug resistance is increasingly observed among the Gram-negative pathogens Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae. Consequently, use of colistin, a polymyxin-type antibiotic, is being reconsidered in particular for treating critically ill patients infected with these pathogens [3] [4] [5] . Unfortunately, the increasing usage of colistin is being associated with the emergence of colistin resistance, in particular in K. pneumoniae [6] [7] [8] [9] [10] [11] .
Alterations in the two-component regulatory systems PmrAB and PhoPQ [8, 9, 12] are known to be involved in polymyxin resistance in K. pneumoniae. Inactivation of the mgrB gene, encoding a negative feedback regulator of the PhoPQ twocomponent system, is also a common mechanism involved in colistin resistance in K. pneumoniae [10, 13] . The reported alterations in the mgrB gene include insertion of several insertions sequences (IS5-like, IS1F-like, ISKpn13, ISKpn14) at different locations in the coding sequence of mgrB and in its promoter region. Non-silent point mutations, premature stop codons, small intragenic deletions and large deletion of the mgrB locus are also known. These alterations result in either reduced or even lack of expression of the mgrB gene leading to upregulation of the phoPQ and pmrHFIJKLM operons that confer resistance to colistin.
Lippa and Goulian have identified MgrB homologues in the genome sequences of various enterobacterial species [14] . Therefore, alterations in mgrB gene expression might possibly be involved in acquisition of colistin resistance in different Klebsiella species.
The aim of this study was to identify the mechanism responsible for resistance to colistin in a K. oxytoca clinical isolate.
Materials and methods

Bacterial strain
The colistin-resistant K. oxytoca clinical isolate was identified using an API20E system and the matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) technique (AB bioMérieux, La Balme-les-Grottes, France). A colistin-susceptible K. oxytoca clinical isolate was used as a wild-type control.
Antimicrobial susceptibility
Antimicrobial susceptibility testing was performed using Etest strips (AB bioMérieux) on Mueller-Hinton agar plates (Bio-Rad, Marnes-la-Coquette, France) with a 0.5 McFarland inoculum. Minimum inhibitory concentrations (MICs) were interpreted as indicated by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines (Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014; http://www.eucast.org). Isolates with colistin MICs of ≤2 g/mL were categorised as susceptible whereas those with MICs of >2 g/mL were resistant.
PCR amplification and sequencing
Whole-cell DNA was extracted using a QIAquick Kit (QIAGEN, Courtaboeuf, France) according to the manufacturer's instructions. The entire pmrA, pmrB, phoP, phoQ and mgrB genes were amplified with specific oligonucleotides primers (Table 1 ) designed with sequences of K. oxytoca KCTC 1686 and E718 genomes available on the National Center for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov.gate2.inist.fr/). Amplified DNA fragments were purified with a QIAquick PCR Purification Kit (QIAGEN). Both strands of the amplification products obtained were sequenced with an ABI 3100 Sequencer (Applied Biosystems, Foster City, CA). The nucleotide and deduced protein sequences were analysed at the NCBI website (http://www.ncbi.nlm.nih.gov) by the Basic Local Alignment Search Tool (BLAST) programme. The insertion sequence (IS) was analysed using the IS finder website (http:// www-is.biotoul.fr).
Complementation assays
The wild-type mgrB gene from a colistin-susceptible K. oxytoca strain and a K. pneumoniae strain, as well as the non-coding mdh sequence [15] , were amplified by PCR using 2X Phusion ® HF Master Mix (Finnzymes; Life Technologies, Illkirch, France) and the primers listed in Table 1 . The amplified fragments were cloned into the plasmid pCR ® -Blunt II-TOPO ® (Invitrogen, Illkirch, France) and the resulting plasmids pTOPO-mgrBKox, pTOPO-mgrBKp and pTOPO-mdh (encoding resistance to Zeocin TM ) were respectively transformed into an electrocompetent colistin-resistant K. oxytoca isolate by electroporation. Electrotransformants were selected by overnight incubation at 37 • C on Mueller-Hinton agar supplemented with 100 g/mL Zeocin TM . MICs of colistin for the K. oxytoca transformants were determined by Etest (bioMérieux).
Results and discussion
Strain and patient features
The colistin-resistant K. oxytoca isolate C24 was recovered in February 2008 from a soft-tissue secretion from a 66-yearold male patient hospitalised for an intra-abdominal infection in Cali, Colombia. The isolate was resistant to broad-spectrum cephalosporins (MICs of ceftazidime and cefotaxime = 32 g/mL), amikacin (MIC = 16 g/mL) and colistin (MIC = 24 g/mL) and was of intermediate susceptibility to ciprofloxacin (MIC = 1 g/mL). The isolate was susceptible to carbapenems (MIC < 0.5 g/mL), gentamicin (MIC = 0.5 g/mL) and tigecycline (MIC = 0.5 g/mL). It harboured a bla CTX-M-15 gene but did not produce any carbapenemase according to the Carba NP test. To our knowledge, the patient had never been treated with any polymyxin.
Modification of mgrB gene expression through insertion of an insertion sequence element
Sequence analysis of the pmrA, pmrB, phoP and phoQ genes known to be involved in lipopolysaccharide (LPS) synthesis showed 100% identity with the genes identified from colistin-susceptible wild-type K. oxytoca isolates (data not shown). Sequence analysis of the mgrB gene as well as upstream-located sequences revealed that an IS of 1196 bp had targeted the upstream vicinity of the mgrB gene between nucleotides −38 and −39 when referring to the start codon of mgrB. This IS was similar to ISKpn26 (differing by only 5 bp) and belonged to the IS5 family. It was bracketed by a 4-bp duplication (TTAT) being the likely signature of a transposition process. The origin of ISKpn26 is K. pneumoniae (https://www-is.biotoul.fr/index. html?is special name=ISKpn26) and it has also been identified in K. oxytoca KONIH1 (GenBank accession no. CP008788.1). In silico analysis of the sequence located upstream of a wild-type mgrB gene revealed a putative promoter sequence made of −35 [TTGAAA] and −10 [TAAACT] boxes separated by 15 bp (Fig. 1) . Insertion of ISKpn26 in isolate C24 led to displacement of this promoter with respect to the mgrB gene position, the corresponding −35 and −10 sequences being consequently very distant from it (Fig. 1) . This suggests a decrease or even lack of expression of the mgrB gene, leading to low or absence of production of the corresponding protein and consequently to acquired resistance to colistin.
Complementation experiments
To confirm whether higher expression of mgrB might restore susceptibility to colistin, complementation of isolate C24 with a plasmid overexpressing mgrB was performed. Transformation assays were either performed with plasmids encoding the MgrB protein of K. oxytoca or K. pneumoniae, respectively. The mgrB gene was provided in trans together with its original promoter in order to ensure it would be expressed at a wild-type level. Following complementation, isolate C24 recovered full susceptibility to colistin with the wild-type MgrB of K. oxytoca (MIC = 0.047 g/mL). Interestingly, the same MIC was obtained after complementation with the MgrB of K. pneumoniae (MIC = 0.047 g/mL). As expected, transformation with plasmid pTOPO-mdh used as a negative control did not restore susceptibility to colistin (MIC = 24 g/mL).
3.4.
Comparison of mgrB gene sequences of K. oxytoca and K. pneumonia Alignment of the mgrB sequences from wild-type K. pneumoniae MGH78578 and K. oxytoca KCTC1686 strains showed that the sequences were almost identical [only a single amino acid substitution (Cys to Tyr at amino acid position 28)]. This result explains why complementation with the mgrB gene of K. pneumoniae restored full susceptibility to colistin in the K. oxytoca isolate. Furthermore, it may suggest that all previously reported alterations of the mgrB gene [10, 13] that have been shown to be the sources of acquired resistance to colistin in K. pneumoniae (such as insertions of IS elements at different locations in the coding sequence of mgrB, non-silent point mutations, premature stop codons, intragenic deletions, etc.) might also be a source of colistin resistance in K. oxytoca.
Conclusion
This study reports on the molecular identification of colistin resistance in K. oxytoca. This resistance mechanism is associated with modification of the biosynthesis pathway of LPS. It is similar to that reported in K. pneumoniae, underlining that common mechanisms of colistin resistance could be identified in different enterobacterial species.
Nucleotide sequence accession number
The nucleotide sequences of the mutated mgrB genes identified in this study have been deposited at DDBJ/EMBL/GenBank under accession no. KP748172.
